Changes in genomic methylation and its significance in carcinogenesis is in the spotlight once again, though the focus is not on the usual suspects, DNA hypermethylation and tumour suppressor gene (TSG) silencing. Several recent reports provide compelling evidence of the relevance of genomic hypomethylation in cancer. These findings provide the best evidence so far that links the loss of DNA methylation and chromosomal instability with cancer development. This review article discusses these recent findings and reflects on the antithetical association between DNA methylation and carcinogenesis and the re-examination of studies performed almost two decades ago. Leukemia (2004)
The two sides of genomic methylationThe genome is exquisitely packaged as a physical entity comprising deoxyribonucleic acid that contains the template for genetic information. In eukaryotes, histone and nonhistone proteins package nuclear DNA into nucleosomes and higher order chromatin structures that make up the chromosome. The modification of genomic DNA and the protein components of chromatin regulate critical molecular processes such as transcriptional control, DNA replication and repair, chromosome segregation and genomic stability. The covalent modification of DNA by methylation is one of the best characterized epigenetic changes. [1][2][3][4][5] The events that regulate chromatin structure and transcriptional competence mediated by changes in epigenetic regulation are also beginning to be understood. 5 Yet, the link between genomic methylation and the progression of cancer has been a source of intense controversy for many years. 6 This has led researchers to investigate the biological role of DNA methylation in cancer. Are elevated or reduced genomic methylation patterns associated with cancer progression? The answer appears to be both, at least in different model systems regardless of whether they be losses or gains in the methylation moiety. Hypermethylation of CpG sequences is generally associated with gene silencing and the identification of putative TSGs and the characterization of bona fide genes continues to grow at a rapid pace. 7,8 There is ample evidence that supports a critical role for promoter methylation in oncogenesis in primary as well as cultured tumour cells. 9,10 Indeed, this change in genomic methylation has become pertinent mark in the field of cancer epigenetics. Recent studies disrupting the DNA methyltransferase genes, DNMT1 and DNMT3b, reduce the overall genomic methylation content and alleviate repression of p16INK4a and TIMP3. 11 Somatic knockout of the DNMT3b gene reduces the global methylation levels by 3% and almost 20% when the DNMT1 gene is disrupted. Unexpectedly, double knockouts (DKOs) show complete genomic methylation loss which correlates with the reversal of gene silencing. 11 DNMT1 null cells treated with the demethylating agent, 5-aza 2 0 -deoxycytidine (5adC), show p16 demethylation and gene reactivation. These results present the most compelling demonstration to date of the involvement of ...